Ten-year experience with pharmacogenetic testing for in a national cancer center in Italy: Lessons learned on the path to implementation.

A Bignucolo, E De Mattia, R Roncato, E Peruzzi, L Scarabel, M D'Andrea, F Sartor, G Toffoli, E Cecchin
Author Information
  1. A Bignucolo: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  2. E De Mattia: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  3. R Roncato: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  4. E Peruzzi: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  5. L Scarabel: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  6. M D'Andrea: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  7. F Sartor: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  8. G Toffoli: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  9. E Cecchin: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.

Abstract

Awareness about the importance of implementing pharmacogenetics in clinical practice to prevent severe side effects related to the use of fluoropyrimidines has been raised over the years. Since 2012 at the National Cancer Institute, CRO-Aviano (Italy), a diagnostic genotyping service was set up. This study aims to describe the evolution of diagnostic activity at our center over the last 10 years as a case example of a successful introduction of pharmacogenetic testing in clinical practice. Data related to the diagnostic activity of in-and out-patients referred to our service between January 2012 and December 2022 were retrieved from the hospital database. diagnostic activity at our center has greatly evolved over the years, shifting gradually from a post-toxicity to a pre-treatment approach. Development of pharmacogenetic guidelines by national and international consortia, genotyping, and IT technology evolution have impacted testing uptake in the clinics. Our participation in a large prospective implementation study (Ubiquitous Pharmacogenomics) increased health practitioners' and patients' awareness of pharmacogenetic matters and provided additional standardized infrastructures for genotyping and reporting. Nationwide test reimbursement together with recommendations by regulatory agencies in Europe and Italy in 2020 definitely changed the clinical practice guidelines of fluoropyrimidines prescription. A dramatic increase in the number of pre-treatment genotyping and in the coverage of new fluoropyrimidine prescriptions was noticed by the last year of observation (2022). The long path to a successful testing implementation in the clinical practice of a National Cancer Center in Italy demonstrated that the development of pharmacogenetic guidelines and genotyping infrastructure standardization as well as capillary training and education activity for all the potential stakeholders are fundamental. However, only national health politics of test reimbursement and clear recommendations by drug regulatory agencies will definitely move the field forward.

Keywords

References

  1. Am J Hum Genet. 2019 Jun 6;104(6):1158-1168 [PMID: 31155283]
  2. Clin Pharmacol Ther. 2013 Dec;94(6):640-5 [PMID: 23988873]
  3. Semin Oncol. 2014 Dec;41(6):798-806 [PMID: 25499638]
  4. J Am Med Inform Assoc. 2018 Jul 1;25(7):893-898 [PMID: 29444243]
  5. Clin Pharmacol Ther. 2018 May;103(5):752-755 [PMID: 29417560]
  6. Clin Pharmacol Ther. 2019 Aug;106(2):313-316 [PMID: 31237679]
  7. Br J Cancer. 2020 Sep;123(5):811-818 [PMID: 32595208]
  8. Eur J Clin Pharmacol. 2017 Oct;73(10):1247-1252 [PMID: 28669097]
  9. Drugs. 2012 May 28;72(8):1057-73 [PMID: 22621694]
  10. Clin Transl Oncol. 2022 Mar;24(3):483-494 [PMID: 34773566]
  11. Front Pharmacol. 2021 Jan 25;11:595219 [PMID: 33568995]
  12. Pharmaceutics. 2022 Oct 06;14(10): [PMID: 36297556]
  13. Hum Genet. 1999 Jan;104(1):1-9 [PMID: 10071185]
  14. Clin Pharmacol Ther. 2017 Jul;102(1):152 [PMID: 30239993]
  15. Curr Drug Metab. 2014 Feb;15(2):209-17 [PMID: 24479687]
  16. PLoS One. 2022 Jun 8;17(6):e0268534 [PMID: 35675343]
  17. Hum Genet. 2010 Nov;128(5):529-38 [PMID: 20803296]
  18. J Oncol Pharm Pract. 2023 Jan;29(1):5-13 [PMID: 34797200]
  19. Clin Pharmacol Ther. 2022 Jul;112(1):62-68 [PMID: 35397172]
  20. Eur J Hum Genet. 2020 Apr;28(4):508-517 [PMID: 31745289]
  21. Clin Cancer Res. 2000 Dec;6(12):4705-12 [PMID: 11156223]
  22. Eur J Cancer. 2004 May;40(7):939-50 [PMID: 15093568]
  23. AMIA Jt Summits Transl Sci Proc. 2017 Jul 26;2017:237-246 [PMID: 28815136]
  24. Clin Pharmacol Ther. 2011 May;89(5):662-73 [PMID: 21412232]
  25. Lancet. 2023 Feb 4;401(10374):347-356 [PMID: 36739136]
  26. Clin Cancer Res. 2011 May 15;17(10):3455-68 [PMID: 21498394]
  27. Int J Cancer. 2015 Dec 15;137(12):2971-80 [PMID: 26099996]
  28. Pharmacogenet Genomics. 2020 Aug;30(6):131-144 [PMID: 32317559]
  29. Pharmacogenomics. 2009 Jun;10(6):931-44 [PMID: 19530960]
  30. JAMA Oncol. 2016 May 01;2(5):655-662 [PMID: 26794347]
  31. Eur J Cancer. 2016 Feb;54:40-48 [PMID: 26716401]
  32. Pharmacogenomics. 2022 Jan;23(1):35-48 [PMID: 34787504]
  33. Pharmacogenomics. 2013 Aug;14(11):1255-72 [PMID: 23930673]
  34. Oncologist. 2021 Dec;26(12):1008-1016 [PMID: 34506675]
  35. J Clin Oncol. 2023 May 20;41(15):2701-2705 [PMID: 36821823]
  36. Curr Pharm Biotechnol. 2017;18(3):204-209 [PMID: 28044932]
  37. Br J Cancer. 2017 Oct 24;117(9):1269-1277 [PMID: 29065426]
  38. Clin Pharmacol Ther. 2019 Apr;105(4):994-1002 [PMID: 30339275]
  39. Pharmacogenomics. 2015 Nov;16(17):1931-41 [PMID: 26555559]
  40. Am J Clin Oncol. 2006 Aug;29(4):371-5 [PMID: 16891864]
  41. ESMO Open. 2023 Apr;8(2):101197 [PMID: 36989883]
  42. Lancet Oncol. 2015 Dec;16(16):1639-50 [PMID: 26603945]
  43. Am J Pharm Educ. 2013 Feb 12;77(1):10 [PMID: 23459098]
  44. Pharmacogenomics. 2017 Jul;18(11):1041-1045 [PMID: 28685652]
  45. Lancet Oncol. 2018 Nov;19(11):1459-1467 [PMID: 30348537]
  46. Genes (Basel). 2019 Apr 04;10(4): [PMID: 30987397]
  47. Clin Pharmacol Ther. 2018 Apr;103(4):599-618 [PMID: 28994452]
  48. Br J Cancer. 2021 Feb;124(3):587-594 [PMID: 33154570]
  49. Front Pharmacol. 2020 Jan 28;10:1609 [PMID: 32047438]
  50. Value Health. 2012 Dec;15(8):1162-71 [PMID: 23244820]
  51. PLoS One. 2016 Oct 20;11(10):e0164972 [PMID: 27764192]
  52. Oncol Res Treat. 2020;43(11):628-636 [PMID: 33099551]
  53. Clin Pharmacol Ther. 2017 Sep;102(3):502-510 [PMID: 28090649]
  54. Pharmacogenomics J. 2024 Mar 15;24(2):9 [PMID: 38490995]
  55. Eur J Cancer. 2020 Jan;124:37-46 [PMID: 31715555]
  56. Clin Pharmacol Ther. 2018 Feb;103(2):210-216 [PMID: 29152729]
  57. Front Pharmacol. 2022 May 18;13:885259 [PMID: 35662713]

Word Cloud

Created with Highcharts 10.0.0genotypingpharmacogeneticclinicalpracticediagnosticactivitytestingimplementationyearsItalycenterguidelinesnationalpharmacogeneticsrelatedfluoropyrimidines2012NationalCancerservicestudyevolutionlastsuccessful2022pre-treatmenthealthtestreimbursementrecommendationsregulatoryagenciesdefinitelypathAwarenessimportanceimplementingpreventseveresideeffectsuseraisedSinceInstituteCRO-Avianosetaimsdescribe10caseexampleintroductionDatain-andout-patientsreferredJanuaryDecemberretrievedhospitaldatabasegreatlyevolvedshiftinggraduallypost-toxicityapproachDevelopmentinternationalconsortiaITtechnologyimpacteduptakeclinicsparticipationlargeprospectiveUbiquitousPharmacogenomicsincreasedpractitioners'patients'awarenessmattersprovidedadditionalstandardizedinfrastructuresreportingNationwidetogetherEurope2020changedprescriptiondramaticincreasenumbercoveragenewfluoropyrimidineprescriptionsnoticedyearobservationlongCenterdemonstrateddevelopmentinfrastructurestandardizationwellcapillarytrainingeducationpotentialstakeholdersfundamentalHoweverpoliticscleardrugwillmovefieldforwardTen-yearexperiencecancerItaly:LessonslearnedCDSSDPYDphenotyping

Similar Articles

Cited By